Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mar

Today In Oncology

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Related Videos

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma

Hypofractionated Locoregional RT in Early Breast Cancer

Melanoma-Specific Survival With Sentinel Lymph Node Biopsy

Breast Cancer Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy

AMA Survey Finds Rapid Growth in Physician AI Adoption